MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients

Journal of Neuroinflammation

Volumn 13, Issue 1, 2016, Pages

  Pache, Florence ^a   Zimmermann, Hanna ^a   Mikolajczak, Janine ^a   Schumacher, Sophie ^a   Lacheta, Anna ^a   Oertel, Frederike C ^a   Bellmann Strobl, Judith ^a,j   Jarius, Sven ^b   Wildemann, Brigitte ^b   Reindl, Markus ^c   Waldman, Amy ^d   Soelberg, Kerstin ^e,f   Asgari, Nasrin ^e,f   Ringelstein, Marius ^g   Aktas, Orhan ^g   Gross, Nikolai ^h   Buttmann, Mathias ⁱ   Ach, Thomas ⁱ   Ruprecht, Klemens ^a   Paul, Friedemann ^a,j   Brandt, Alexander U ^a   more..

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e LILLEBAELT HOSPITAL   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ UNIVERSITY OF WÜRZBURG   (Germany)

^j MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

more..

Author keywords

Aquaporin 4 antibodies (AQP4 IgG); Devic syndrome; Myelin oligodendrocyte glycoprotein antibodies (MOG IgG); Neuromyelitis optica; Neuromyelitis optica spectrum disorders (NMOSD); NMO IgG; Optic neuritis; Optical coherence tomography; Retinal neuro axonal damage; Visual acuity; Visual evoked potentials

Indexed keywords

AQUAPORIN 4 ANTIBODY; IMMUNOGLOBULIN G; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEIN ANTIBODY; AQUAPORIN 4;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INNER NUCLEAR LAYER VOLUME; MALE; MEDICAL HISTORY; MYELOOPTIC NEUROPATHY; NEUROMYELITIS OPTICA SPECTRUM DISORDER; ONSET AGE; OPTIC NEURITIS; OPTICAL COHERENCE TOMOGRAPHY; OUTER RETINAL LAYER VOLUME; PERIPAPILLARY RETINAL NERVE FIBER LAYER THICKNESS; RECURRENCE RISK; RETINA GANGLION CELL; RETINA INJURY; RETINAL INNER PLEXIFORM LAYER; RETINAL NERVE FIBER LAYER THICKNESS; RETROSPECTIVE STUDY; VISUAL ACUITY; VISUAL EVOKED POTENTIAL; VISUAL IMPAIRMENT; VISUAL SYSTEM PARAMETERS; BLOOD; CLINICAL TRIAL; COMPLICATION; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; NONPARAMETRIC TEST; PATHOLOGY; PATHOPHYSIOLOGY; PHOTOSTIMULATION; PHYSIOLOGY; REACTION TIME; RETINA; RETINAL DISEASES; VISUAL SYSTEM;

ADULT; AQUAPORIN 4; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; OPTIC NEURITIS; PHOTIC STIMULATION; REACTION TIME; RETINA; RETINAL DISEASES; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VISUAL PATHWAYS;

EID: 84994036979     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-016-0720-6     Document Type: Article

References (42)

1. Reindl M, Di Pauli F, Rostásy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013;9:455-61.
2. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011;8:184.
3. Rostásy K, Mader S, Hennes EM, Schanda K, Gredler V, Guenther A, et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult Scler J. 2013;19:1052-9.
4. Sato DK, Callegaro D, Lana-Peixoto MA, Waters PJ, Jorge FM, de H, Takahashi T, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474-81.
5. Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol. 2014;71:276-83.
6. Saadoun S, Waters P, Owens GP, Bennett JL, Vincent A, Papadopoulos MC. Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain. Acta Neuropathol Commun. 2014;2:35.
7. Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry. 2015;86:265-72.
8. Kim S-M, Woodhall MR, Kim J-S, Kim S-J, Park KS, Vincent A, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflammation [Internet]. 2015 [cited 2016 Feb 18];2. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608758/
9. Höftberger R, Sepulveda M, Armangue T, Blanco Y, Rostásy K, Cobo Calvo A, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler J. 2015;21:866-74.
10. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflammation [Internet]. 2015 [cited 2015 Feb 23];2. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309526/
11. Reindl M, Rostasy K. MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflammation [Internet]. 2015 [cited 2015 Dec 16];2. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309525/
12. Aktas O. Collateral benefit: the comeback of MOG antibodies as a biomarker in neurological practice. J Neurol Neurosurg Psychiatry. 2015;86:243.
13. Ikeda K, Kiyota N, Kuroda H, Sato DK, Nishiyama S, Takahashi T, et al. Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. Mult Scler J. 2015;21:656-9.
14. Spadaro M, Gerdes LA, Mayer MC, Ertl-Wagner B, Laurent S, Krumbholz M, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. Ann Clin Transl Neurol. 2015;2:295-301.
15. Di Pauli F, Höftberger R, Reindl M, Beer R, Rhomberg P, Schanda K, et al. Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology. Neurol Neuroimmunol Neuroinflammation. 2015;2:e175.
16. Jarius S, Metz I, König FB, Ruprecht K, Reindl M, Paul F, et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in "pattern II multiple sclerosis" and brain biopsy findings in a MOG-IgG-positive case. Mult Scler J. 2016. doi: 10.1177/1352458515622986.
17. Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176:149-64.
18. Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, et al. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler J. 2015;21:678-88.
19. Kaufhold F, Zimmermann H, Schneider E, Ruprecht K, Paul F, Oberwahrenbrock T, et al. Optic Neuritis Is Associated with Inner Nuclear Layer Thickening and Microcystic Macular Edema Independently of Multiple Sclerosis. PLoS One. 2013;8:e71145.
20. Sotirchos ES, Saidha S, Byraiah G, Mealy MA, Ibrahim MA, Sepah YJ, et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology. 2013;80:1406-14.
21. Martinez-Hernandez E, Sepulveda M, Rostásy K, et al. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis. JAMA Neurol. 2015;72:187-93.
22. Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry. 2016;87(4):446-8.
23. Ramanathan S, Reddel SW, Henderson A, Parratt JDE, Barnett M, Gatt PN, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflammation. 2014;1:e40.
24. Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflammation. 2015;2:e131.
25. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016. doi: 10.1186/s12974-016-0718-0.
26. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016. doi: 10.1186/s12974-016-0717-1.
27. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-52.
28. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177-89.
29. Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, Stoecker W, et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci. 2010;291:52-6.
30. Jarius S, Wildemann B. Aquaporin-4 Antibodies (NMO-IgG) as a Serological Marker of Neuromyelitis Optica: A Critical Review of the Literature. Brain Pathol. 2013;23:661-83.
31. Tewarie P, Balk L, Costello F, Green A, Martin R, Schippling S, et al. The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment. PLoS One. 2012;7:e34823.
32. Oberwahrenbrock T, Weinhold M, Mikolajczak J, Zimmermann H, Paul F, Beckers I, et al. Reliability of Intra-Retinal Layer Thickness Estimates. PLoS One. 2015;10:e0137316.
33. Emmerson-Hanover R, Shearer DE, Creel DJ, Dustman RE. Pattern reversal evoked potentials: gender differences and age-related changes in amplitude and latency. Electroencephalogr Clin Neurophysiol. 1994;92:93-101.
34. Holladay JT. Proper method for calculating average visual acuity. J Refract Surg Thorofare NJ. 1997;13:388-91.
35. R Development Core Team. R: a language and environment for statistical computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2010. Available from: http://www.R-project.org
36. Ratchford JN, Quigg ME, Conger A, Frohman T, Frohman EM, Balcer LJ, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology. 2009;73:302-8.
37. Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. J Neuroinflammation. 2016. doi: 10.1186/s12974-016-0719-z.
38. Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.
39. Schneider E, Zimmermann H, Oberwahrenbrock T, Kaufhold F, Kadas EM, Petzold A, et al. Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS One. 2013;8:e66151.
40. Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, et al. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography. Mult Scler. 2015;21(6):678-88.
41. Galetta SL, Villoslada P, Levin N, Shindler K, Ishikawa H, Parr E, et al. Acute optic neuritis. Neurol Neuroimmunol Neuroinflammation [Internet]. 2015 [cited 2016 Jun 2];2. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516397/
42. Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2013;261:1-16.